These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 34849998)
1. The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections. Bouza E J Antimicrob Chemother; 2021 Nov; 76(Suppl 4):iv38-iv45. PubMed ID: 34849998 [TBL] [Abstract][Full Text] [Related]
2. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684 [TBL] [Abstract][Full Text] [Related]
3. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Shortridge D; Kantro V; Castanheira M Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238 [TBL] [Abstract][Full Text] [Related]
4. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam. Wenzler E; Scoble PJ Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557 [TBL] [Abstract][Full Text] [Related]
5. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
6. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. Kanj SS; Bassetti M; Kiratisin P; Rodrigues C; Villegas MV; Yu Y; van Duin D Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918 [TBL] [Abstract][Full Text] [Related]
8. Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination. Mansour H; Ouweini AEL; Chahine EB; Karaoui LR Am J Health Syst Pharm; 2021 Mar; 78(8):674-683. PubMed ID: 33580649 [TBL] [Abstract][Full Text] [Related]
9. Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria. Patel TS; Pogue JM; Mills JP; Kaye KS Future Microbiol; 2018 Jul; 13(9):971-983. PubMed ID: 29692218 [TBL] [Abstract][Full Text] [Related]
10. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections. Dhillon S Drugs; 2018 Aug; 78(12):1259-1270. PubMed ID: 30128699 [TBL] [Abstract][Full Text] [Related]
11. Nelson K; Rubio-Aparicio D; Sun D; Dudley M; Lomovskaya O Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32482673 [TBL] [Abstract][Full Text] [Related]
12. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens. Karaiskos I; Galani I; Souli M; Giamarellou H Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244 [TBL] [Abstract][Full Text] [Related]
13. An Update on Existing and Emerging Data for Meropenem-Vaborbactam. Shoulders BR; Casapao AM; Venugopalan V Clin Ther; 2020 Apr; 42(4):692-702. PubMed ID: 32147146 [TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections. Sader HS; Castanheira M; Duncan LR; Mendes RE Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144 [TBL] [Abstract][Full Text] [Related]
15. Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem/Cilastatin-Relebactam to Target Hayden DA; White BP; Bennett KK J Pharm Technol; 2020 Oct; 36(5):202-210. PubMed ID: 34752560 [No Abstract] [Full Text] [Related]
16. Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections. Albin OR; Patel TS; Kaye KS Expert Rev Anti Infect Ther; 2018 Dec; 16(12):865-876. PubMed ID: 30372359 [TBL] [Abstract][Full Text] [Related]
17. Synergistic effect of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales. Shi S; Zhang X; Yao Z; Xu M; Zhou B; Liu Q; Zhang Y; Zhou C; Zhou T; Ye J J Antimicrob Chemother; 2022 Apr; 77(5):1301-1305. PubMed ID: 35165715 [TBL] [Abstract][Full Text] [Related]
18. An evaluation of meropenem/vaborbactam for the treatment of nosocomial pneumonia. Groft LM; Claeys KC; Heil EL Expert Opin Pharmacother; 2021 Feb; 22(3):265-271. PubMed ID: 33090037 [No Abstract] [Full Text] [Related]
19. Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae. Jorgensen SCJ; Rybak MJ Pharmacotherapy; 2018 Apr; 38(4):444-461. PubMed ID: 29427523 [TBL] [Abstract][Full Text] [Related]
20. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Bader MS; Loeb M; Leto D; Brooks AA Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]